Legal cultivation of cannabis gets a step closer
Legislation allowing the cultivation of cannabis for the manufacture of therapeutic products hits parliament today – and it appears it has a great chance.
This morning health minister Susan Ley announced the introduction of legislation eight weeks in the making, describing it as the “missing piece” of medical cannabis legislation.
Amendments to the existing Narcotics Drugs Act are being pursued to allow the controlled cultivation of cannabis of medicinal or scientific purposes into a single unifying scheme – which would be a first for Australia.
At the moment there are provisions to allow the legal production and distribution of medical cannabis products, but there’s no single unifying scheme allowing for the cultivation of cannabis for therapeutic products.
Hence, Ley described it as a “missing piece”.
“For Australia, this is the missing piece in a patient’s journey,” Ley said in a statement.
“Importantly, having a safe, legal and reliable source of products will ensure medical practitioners are now at the centre of the decision making process on whether medicinal cannabis may be beneficial for their patient.”
It would appear that on a sentiment basis at least the legislation will enjoy bi-partisan support.
In 2014 a similar bill was introduced by the Greens but endorsed by both Liberal and Labor senators that would allow a national regulator – demonstrating that the issue has broad bi-partisan support.
Should the latest bill pass both houses, it would open the way for companies in the medical cannabis space to take more control of the supply chain within Australia.
Companies which would benefit include MMJ Phytotech (ASX:MMJ) and MGC Pharmaceuticals (ASX:MXC).
After merging with Canadian-based MMJ Bioscience last year MMJ is developing a range of CBD-based products aimed at the growing global market for medicinal cannabis, in partnership with a leading scientific research centre in Israel.
MMJ already has sold its first CBD-based pill via European distribution partners, with the sale taking place late last year.
MGC Pharmaceuticals (ASX:MXC) is aiming to produce high quality resins, oils, salves and creams made from CBD with growing operations in Slovenia and Namibia.
Last year, MXC became the first Australian registered company to gain permission to grow, process, import and export an unlimited quantity of Cannabis Sativa L (hemp) and its products.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.